JNPMEDI participated in a digital twin based DTx clinical trial project supported by the Korean Ministry of Trade, Industry and Energy.

JNPMEDI participated in a digital twin-based DTx clinical trial project supported by the Korean Ministry of Trade, Industry and Energy.

JNPMEDI participated in a digital twin based DTx clinical trial project supported by the Korean Ministry of Trade, Industry and Energy.

JNPMEDI announced on the 6th that it will participate in the digital healthcare business of the Korean Ministry of Trade, Industry and Energy. The digital healthcare business is a project to develop an online platform that supports the entire cycle of clinical trials for Digital Therapeutics (DTx). Using digital twin-based experiential technology, the digital healthcare business will run until 2025.

To support the development of digital treatments specialized for children, adolescents, and mental diseases, this platform provides clinical trial guidance and hands-on content through the virtual world environment during the recruitment process.

Children and adolescents with high digital literacy are familiar with non-face-to-face and are very familiar with the digital environment, so it is expected that participation in clinical trials will be maximized by using virtual environment-related technologies such as VR and XR.

In fact, overseas, various attempts are being made in anticipation of expanding the concept of Decentralized Clinical Trials (DCT) conducted non-face-to-face without visiting a hospital to quickly predict clinical trial results through digital twins of patients participating in clinical trials.

JNPMEDI participates as a joint R&D institution along with Yonsei University's Industry-Academic Cooperation Group and Urban Union and provides clinical trial data management services in the process of developing a total of six digital treatments.

In addition, JNPMEDI plans to develop a clinical trial methodology and corporate demonstration guidelines for licensing specialized in digital therapeutics in this project and serves as an advisory for digital therapeutics developers to conduct clinical trials.